InflaRx GmbH
- Address
- Winzerlaer Strasse 2, Ammerbach
Sponsor Overview
Specializations
Dermatology and Inflammatory Skin Disease
Clinical research is concentrated in ulcerative pyoderma gangrenosum, with additional activity in hidradenitis suppurativa and chronic spontaneous urticaria. These programmes reflect a focus on difficult-to-treat inflammatory dermatologic disorders with significant symptom burden.
- Ulcerative pyoderma gangrenosum
- Hidradenitis suppurativa
- Chronic spontaneous urticaria
Study activity includes patients with moderate to severe disease as well as healthy volunteers for comparative safety and pharmacology assessments.
Immunology and Complement-Mediated Inflammation
The sponsor’s portfolio includes investigation of vilobelimab in pyoderma gangrenosum, indicating interest in immune-driven inflammatory pathways relevant to refractory skin disease.
- Immune-mediated inflammation
- Complement pathway targeting
- Neutrophilic dermatoses
This area links systemic inflammatory biology with cutaneous disease expression.
Small-Molecule Therapeutics and Pharmacokinetics
Research involving INF904 centers on safety, pharmacokinetics, bioavailability, food effects, and metabolite profiling, with evaluation in both patient populations and healthy participants.
- Oral formulation development
- Bioavailability assessment
- Metabolite profiling
The programme spans early clinical characterization alongside disease-focused evaluation in CSU and HS.
Clinical Pharmacology and Healthy Volunteer Studies
Trials in healthy male participants support foundational clinical pharmacology work for izicopan and related compounds, complementing patient studies in inflammatory conditions.
- Single-dose pharmacology
- Mass balance evaluation
- Metabolic characterization
These studies contribute to understanding exposure, disposition, and safety across early human research settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Vilobelimab in Ulcerative Pyoderma Gangrenosum: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial |  Belgium France Germany Hungary Italy Poland Spain The Netherlands | Not Recruiting |
| Phase 1 Open-Label Single-Dose Mass Balance and Metabolite Profiling Study of 14C-Labeled Izicopan (INF904) in Healthy Male Participants | The Netherlands | Not Recruiting |
| Phase 1 Study on Bioavailability, Food Effect, and Safety of INF904 Capsule Formulations in Healthy Volunteers | The Netherlands | Not Recruiting |
| Phase 2a Open-Label Basket Study Evaluating Safety and Pharmacokinetics of INF904 in Moderate to Severe Chronic Spontaneous Urticaria and Hidradenitis Suppurativa |  Bulgaria Germany Greece Poland | Not Recruiting |
Data & Insights
This sponsor works with 11 molecules, of which 3 are not being studied by other sponsors.
This sponsor has worked with 48 sites across their trial portfolio.
Therapeutic Focus
- 1.Not possible to specify2 trials220 other sponsors
- 2.Skin and Connective Tissue Diseases2 trials247 other sponsors
Partnered Research Centres
48 centres- Address
- Ulitsa Persenk 19, Enter B Floor 1 App 13, 1407 Sofia
- Address
- Num Voie 47 A 83, 47 Boulevard De L Hopital, 75013 Paris
- Address
- Via Cherasco 15, 10126 Turin
- Address
- Via Pietro Albertoni 15, 40138 Bologna
- Address
- 1 Place Alexis Ricordeau, 44000 Nantes
- Address
- 1 Place Du Docteur Joseph Baylac, 31300 Toulouse
Want to get in touch with this sponsor?
Send a question and we'll pass it on to InflaRx GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.